ALKBH5 plays an antitumor role in CRC by increasing the stability of FOXO3 by attenuating the level of its m6A modification, and FOXO3 targets miR-21 and promotes the expression of SPRY2, providing a new direction for CRC therapy [13]. This evidence concerns the gene ALKBH5 and colorectal carcinoma.